To view the complete agenda and full line up of speakers & their presentations please download the agenda to your right.

Oxford Global is proud to present the Artificial Intelligence in Drug Development Congress on the 27 – 28 September 2017 in London, UK. This congress will bring together key opinion leaders and senior industry experts in AI to discuss the innovative application of AI to drug development and clinical research. These topics have been compiled as a result of a comprehensive research process undertaken with an expert advisory board with members including Senior Directors and Professors from global pharmaceutical organisations, biotech companies and leading research institutions.

From the length of time needed to bring a drug to market, to the rising research costs, to high failure rates, the drug industry faces significant issues. The concept of artificial intelligence is therefore increasingly seen as the future of drug discovery. The ability of AI to rapidly analyse vast quantities of data could make it an invaluable part of the drug development process, increasing the speed with which a drug reaches market and therefore lowering costs. AI could also be used to design more effective clinical trials and quickly ‘read’ the trial data – increasing the speed and likely success of the trials.

Reflecting this, on Day 1 we concentrate on the application of AI in Drug Discovery and Development. It considers the use of AI to identify and analyse biological markers, alongside innovative uses of high-throughput screening and genomics. Further sessions focus on pharma case studies on the use of machine learning, data analytics and AI.

These case studies continue on Day 2, centring on the use of AI in Big Data and Clinical Research Development, primarily through machine learning and data analytics. AI could increase the efficacy of clinical trials through the stratification of patients and the application of data analytics. Further talks include discussions of AI to support Real World Evidence and a panel discussion of data collaboration through AI.

Finally, we will consider the use of AI to develop diagnostic and imaging tools in Healthcare. This increasingly key area is already being implemented through novel diagnostics, remote patient monitoring and patient-specific alerts.

Day 1 Stream 1 – Artificial Intelligence (AI) in Drug Discovery and Development

Drug Development based on biological markers

Machine learning and Data Analysis

High-throughput screening and AI

AI in Platforms and tools: supporting the modelling and real world data teams and research labs globally

Genomics, Big Data Analysis and Deep Learning for In Silico Drug Discovery and Drug Repurposing for Aging and Age-related diseases

AI in Drug Design

Day 2 Stream 1 – Part 1

Artificial Intelligence (AI) in Big Data and Clinical Research Development

Patient Stratification in clinical trials

Applying Machine Learning and Data Analytics to clinical

AI in Cloud computing and Big data

Supporting Real World Evidence and E Health Support

AI, Robotics and Machine Learning: leading data science and machine learning teams working across therapeutic areas in the late stage drug development pipeline

Strategy Series

The Artificial Intelligence in Drug Development Congress is one of Oxford Global’s highly successful life science events. For more information on other events in this series, please see the details below: